Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s13238-020-00738-2 http://scihub22266oqcxt.onion/10.1007/s13238-020-00738-2 32519302!7282699!32519302     free     free     free Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Protein+Cell 2020 ; 11 (10): 707-722 Nephropedia Template TP {{tp|p=32519302|t=2020. Mesenchymal stem cell therapy for acute respiratory distress syndrome: from basic to clinics |pdf=|usr=}}{{32519302}} gab.com Text Mesenchymal stem cell therapy for acute respiratory distress syndrome: from basic to clinics JO: Protein Cell http://www.kidney.de/pget.php?&tw=1&pmid=32519302 #FOAvip The 2019 novel coronavirus disease (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has occurred in China and around the world. SARS-CoV-2-infected patients with severe pneumonia rapidly develop acute respiratory distress syndrome (ARDS) and die of multiple organ failure. Despite advances in supportive care approaches, ARDS is still associated with high mortality and morbidity. Mesenchymal stem cell (MSC)-based therapy may be an potential alternative strategy for treating ARDS by targeting the various pathophysiological events of ARDS. By releasing a variety of paracrine factors and extracellular vesicles, MSC can exert anti-inflammatory, anti-apoptotic, anti-microbial, and pro-angiogenic effects, promote bacterial and alveolar fluid clearance, disrupt the pulmonary endothelial and epithelial cell damage, eventually avoiding the lung and distal organ injuries to rescue patients with ARDS. An increasing number of experimental animal studies and early clinical studies verify the safety and efficacy of MSC therapy in ARDS. Since low cell engraftment and survival in lung limit MSC therapeutic potentials, several strategies have been developed to enhance their engraftment in the lung and their intrinsic, therapeutic properties. Here, we provide a comprehensive review of the mechanisms and optimization of MSC therapy in ARDS and highlighted the potentials and possible barriers of MSC therapy for COVID-19 patients with ARDS. Twit Text FOAVip Mesenchymal stem cell therapy for acute respiratory distress syndrome: from basic to clinics ????Protein Cell http://www.kidney.de/pget.php?&tw=1&pmid=32519302 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32519302 #FOAvip English Wikipedia <ref>{{Cite pmid|32519302}}</ref> Mesenchymal stem cell therapy for acute respiratory distress syndrome: from basic to clinics #MMPMID32519302 Qin H; Zhao A Protein Cell 2020[Oct]; 11 (10): 707-722 PMID32519302show ga The 2019 novel coronavirus disease (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has occurred in China and around the world. SARS-CoV-2-infected patients with severe pneumonia rapidly develop acute respiratory distress syndrome (ARDS) and die of multiple organ failure. Despite advances in supportive care approaches, ARDS is still associated with high mortality and morbidity. Mesenchymal stem cell (MSC)-based therapy may be an potential alternative strategy for treating ARDS by targeting the various pathophysiological events of ARDS. By releasing a variety of paracrine factors and extracellular vesicles, MSC can exert anti-inflammatory, anti-apoptotic, anti-microbial, and pro-angiogenic effects, promote bacterial and alveolar fluid clearance, disrupt the pulmonary endothelial and epithelial cell damage, eventually avoiding the lung and distal organ injuries to rescue patients with ARDS. An increasing number of experimental animal studies and early clinical studies verify the safety and efficacy of MSC therapy in ARDS. Since low cell engraftment and survival in lung limit MSC therapeutic potentials, several strategies have been developed to enhance their engraftment in the lung and their intrinsic, therapeutic properties. Here, we provide a comprehensive review of the mechanisms and optimization of MSC therapy in ARDS and highlighted the potentials and possible barriers of MSC therapy for COVID-19 patients with ARDS. |*Betacoronavirus[MESH] |*Mesenchymal Stem Cell Transplantation/methods[MESH] |*Pandemics[MESH] |Adoptive Transfer[MESH] |Alveolar Epithelial Cells/pathology[MESH] |Animals[MESH] |Apoptosis[MESH] |Body Fluids/metabolism[MESH] |CD4-Positive T-Lymphocytes/immunology[MESH] |COVID-19[MESH] |Clinical Trials as Topic[MESH] |Coinfection/prevention & control/therapy[MESH] |Coronavirus Infections/*complications/immunology[MESH] |Disease Models, Animal[MESH] |Endothelial Cells/pathology[MESH] |Extracorporeal Membrane Oxygenation[MESH] |Genetic Therapy/methods[MESH] |Genetic Vectors/administration & dosage/therapeutic use[MESH] |Humans[MESH] |Immunity, Innate[MESH] |Inflammation Mediators/metabolism[MESH] |Lung/pathology/physiopathology[MESH] |Mesenchymal Stem Cells/physiology[MESH] |Multiple Organ Failure/etiology/prevention & control[MESH] |Pneumonia, Viral/*complications/immunology[MESH] |Respiratory Distress Syndrome/immunology/pathology/*therapy[MESH] |SARS-CoV-2[MESH]Mesenchymal stem cell therapy for acute respiratory distress syndrome:(epmc).pdf DeepDyve Pubget Overpricing